Peptide Conjugates

Native peptides face three pharmacological challenges: rapid enzymatic degradation, short half-life, and poor membrane permeability. Peptide conjugation — covalently attaching a non-peptide moiety — addresses these limitations while retaining the peptide's biological activity. The strategy has produced some of the most commercially successful drugs in medicine.

Fatty acid acylation

Attaching a fatty acid chain to the peptide enables reversible albumin binding. Albumin has a plasma half-life of ~19 days; anything bound to it is shielded from renal filtration and enzymatic degradation.

Key examples:

• Semaglutide — a C-18 fatty diacid chain enables albumin binding, extending half-life from GLP-1's native 2 minutes to ~168 hours (once-weekly dosing)
• Liraglutide — a C-16 fatty acid chain extends GLP-1 half-life to ~13 hours (once-daily dosing)
• Insulin detemir and insulin degludec — fatty acid acylation of insulin for extended-action profiles

The fatty acid chain length determines albumin binding affinity and thus half-life: longer chains = stronger binding = longer duration.

PEGylation

Polyethylene glycol (PEG) conjugation increases the hydrodynamic radius of a peptide, reducing renal clearance and shielding it from proteases. PEGylation was the first widely used peptide conjugation strategy.

In the peptide space:

• PEG-MGF — PEGylated mechano growth factor. The PEG moiety extends the very short half-life of native MGF (minutes) to several hours, allowing less frequent dosing
• CJC-1295 DAC — the Drug Affinity Complex is a maleimide-based conjugation to lysine residues, enabling covalent albumin binding in vivo (distinct from traditional PEGylation but conceptually related)

Limitations of PEGylation:

• Large PEG chains can reduce receptor binding affinity
• PEG accumulation in tissues (vacuolation) has been observed in animal studies at high doses
• Anti-PEG antibodies can develop with repeated exposure, reducing efficacy

Cell-penetrating peptide (CPP) conjugates

Cell-penetrating peptides (TAT, penetratin, polyarginine sequences) can be fused to cargo peptides to enable intracellular delivery. This is relevant for peptides whose targets are intracellular — transcription factors, kinases, or mitochondrial targets.

Research applications:

• SS-31 (elamipretide) contains a cell-penetrating motif (D-Arg-dimethylTyr-Lys-Phe) that enables mitochondrial inner membrane targeting — something conventional peptides cannot achieve
• KPV's anti-inflammatory activity involves intracellular entry and direct NF-κB inhibition, potentially facilitated by its small size and charge characteristics

Lipidation beyond fatty acids

Modifications beyond simple fatty acid attachment:

• Palmitoylation — attaching palmitic acid (C-16) to cosmetic peptides improves skin penetration. Palmitoyl tripeptide-1 (PAL-GHK), palmitoyl tetrapeptide-7, and palmitoyl pentapeptide-4 (Matrixyl) all use this strategy
• Myristoylation — C-14 fatty acid attachment, used in some research peptides
• Cholesterol conjugation — cholesterol-peptide conjugates for enhanced membrane interaction and extended circulation

Peptide-drug conjugates (PDCs)

An emerging field analogous to antibody-drug conjugates (ADCs). A peptide targeting a specific receptor is conjugated to a cytotoxic or therapeutic payload. The peptide provides tissue selectivity; the payload provides the therapeutic effect.

Clinical stage examples:

• Lutathera (¹⁷⁷Lu-DOTATATE) — a somatostatin analog conjugated to a radioactive isotope for targeted radiotherapy of neuroendocrine tumors. The peptide targets somatostatin receptors on tumor cells; the radioisotope provides the cytotoxic effect
• Various GnRH-conjugated chemotherapeutics under investigation for hormone-receptor-positive cancers

Multi-agonist design

Modern peptide engineering creates single molecules that activate multiple receptors — a form of intramolecular conjugation:

• Tirzepatide — single peptide chain engineered to activate both GLP-1R and GIPR
• Retatrutide — single chain activating GLP-1R, GIPR, and glucagon receptor
• CagriSema — not a single molecule but a co-formulation of semaglutide + cagrilintide (amylin analog) in one injection

These represent the frontier of peptide design: rationally engineered molecules that combine multiple biological activities in a single therapeutic agent.

Impact on the research peptide landscape

Understanding conjugation explains several features of common research peptides:

• Why CJC-1295 (DAC) lasts days while CJC-1295 (no DAC) lasts minutes — the DAC modification enables in-vivo albumin conjugation
• Why PEG-MGF is preferred over native MGF — PEGylation provides a practical half-life
• Why palmitoylated peptides (Matrixyl, PAL-GHK) are used in skincare while their parent peptides are not — lipidation enables dermal penetration
• Why semaglutide can be dosed weekly while native GLP-1 is degraded in minutes — fatty acid acylation fundamentally changes pharmacokinetics